Skip to main content
SpringerLink
Log in

Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Objective

Heart failure (HF) is associated with an increased risk of dementia, and studies show that dyslipidemia may be involved in the pathogenesis of dementia. However, it is unclear whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are associated with a lower risk of dementia in HF patients. The present study examines the effectiveness of statins to prevent dementia in HF patients.

Methods

This retrospective longitudinal study used a cohort of patients with HF identified from a local US Medicare Advantage Prescription Drug plan to examine the incidence of dementia with up to 3 years of follow-up. A multivariable time-dependent Cox model and inverse-probability-of-treatment weighting (IPTW) of the marginal structural model were used to estimate the risk of developing dementia. Adjusted dementia rate ratios were estimated among current and former statin users, as compared with nonusers.

Results

The study included a total of 8062 HF patients (mean age 74.47 ± 9.21 years), of whom 1135 (14.08 %) were diagnosed with dementia during a median follow-up of 22 months. Using the time-dependent Cox model, the adjusted dementia rate ratios among current and former users were 0.93 (95 % confidence interval [CI] 0.71–1.21) and 0.99 (95 % CI 0.79–1.25), respectively. Use of IPTW resulted in similar findings of 1.24 (95 % conservative CI 0.89–1.72) among current users and 0.94 (95 % conservative CI 0.67–1.31) among former users as compared with nonusers.

Conclusion

This study found no difference in the risk of dementia among current and former users of statins as compared with nonusers in an already at-risk HF population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166(9):1003–8. doi:10.1001/archinte.166.9.1003.

    Article  PubMed  Google Scholar 

  2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220. doi:10.1161/CIR.0b013e31823ac046.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Heckman GA, Patterson CJ, Demers C, St Onge J, Turpie ID, McKelvie RS. Heart failure and cognitive impairment: challenges and opportunities. Clin Interv Aging. 2007;2(2):209–18.

    PubMed Central  PubMed  Google Scholar 

  4. Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol Ser A Biol Sci Med Sci. 2001;56(2):M88–96.

    Article  CAS  Google Scholar 

  5. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226–33.

    Article  PubMed  Google Scholar 

  6. Marengoni A, Corrao S, Nobili A, Tettamanti M, Pasina L, Salerno F, et al. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry. 2011;26(9):930–6. doi:10.1002/gps.2627.

    Article  CAS  PubMed  Google Scholar 

  7. Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry. 2009;80(11):1194–201. doi:10.1136/jnnp.2009.176818.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Wenger NK, Scheidt S, Weber M. Cardiovascular risk factors, cardiovascular disease, cardiovascular drug therapies, and dementia/cognitive dysfunction: how do the pieces of the puzzle fit together? Am J Geriatr Cardiol. 2007;16(3):133–5.

    Article  PubMed  Google Scholar 

  9. Cole SL, Vassar R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22. doi:10.1186/1750-1326-2-22.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Decarli C. Vascular factors in dementia: an overview. J Neurol Sci. 2004;226(1–2):19–23. doi:10.1016/j.jns.2004.09.005.

    Article  PubMed  Google Scholar 

  11. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12(2):105–12.

    Article  CAS  PubMed  Google Scholar 

  12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science (New York, NY). 2002;297(5580):353–6. doi:10.1126/science.1072994.

    Article  CAS  Google Scholar 

  13. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J Lipid Res. 2005;46(5):949–68. doi:10.1194/jlr.M400486-JLR200.

    Article  CAS  PubMed  Google Scholar 

  14. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  15. Reiss AB, Siller KA, Rahman MM, Chan ES, Ghiso J, de Leon MJ. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease. Neurobiol Aging. 2004;25(8):977–89. doi:10.1016/j.neurobiolaging.2003.11.009.

    Article  CAS  PubMed  Google Scholar 

  16. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705–14. doi:10.1001/archneur.61.5.705.

    Article  PubMed Central  PubMed  Google Scholar 

  17. van Exel E, de Craen AJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane PW, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Annals of Neurology. 2002;51(6):716–21. doi:10.1002/ana.10220.

    Article  PubMed  Google Scholar 

  18. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev (Online). 2009;(2):CD003160. doi:10.1002/14651858.CD003160.pub2.

  19. McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev (Online). 2010;(8):CD007514. doi:10.1002/14651858.CD007514.pub2.

  20. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci. 2001;98(10):5856–61. doi:10.1073/pnas.081620098.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci. 1998;95(11):6460–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37(6):1450–7.

    Article  CAS  PubMed  Google Scholar 

  23. Ruocco A, Postiglione A, Santillo M, Seru R, Avvedimento EV, Cuda G, et al. New possible role of statins in age-related diseases. J Am Geriatr Soc. 2002;50(12):2099–100.

    Article  PubMed  Google Scholar 

  24. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Investig. 2002;110(3):285–8. doi:10.1172/jci16421.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Xiong GL, Benson A, Doraiswamy PM. Statins and cognition: what can we learn from existing randomized trials? CNS Spectr. 2005;10(11):867–74.

    PubMed  Google Scholar 

  26. Whitfield JF. Can statins put the brakes on Alzheimer’s disease? Expert Opin Investig Drugs. 2006;15(12):1479–85. doi:10.1517/13543784.15.12.1479.

    Article  CAS  PubMed  Google Scholar 

  27. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:71–7. doi:10.1111/j.1600-0404.2006.00688.x.

    Article  CAS  PubMed  Google Scholar 

  28. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378–84.

    Article  PubMed  Google Scholar 

  29. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388–94. doi:10.1212/01.wnl.0000182897.18229.ec.

    Article  CAS  PubMed  Google Scholar 

  30. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheimers Dis. 2008;13(2):187–97.

    CAS  PubMed  Google Scholar 

  31. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344–50. doi:10.1212/01.wnl.0000319647.15752.7b.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Szwast SJ, Hendrie HC, Lane KA, Gao S, Taylor SE, Unverzagt F, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology. 2007;69(19):1873–80. doi:10.1212/01.wnl.0000279333.77404.d7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047–51. doi:10.1001/archneur.62.7.1047.

    Article  PubMed  Google Scholar 

  34. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62(2):217–24. doi:10.1001/archpsyc.62.2.217.

    Article  CAS  PubMed  Google Scholar 

  35. McGuinness B, Passmore P. Can statins prevent or help treat Alzheimer’s disease? J Alzheimers Dis. 2010;20(3):925–33. doi:10.3233/jad-2010-091570.

    PubMed  Google Scholar 

  36. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1):95–102. doi:10.3233/jad-2010-100180.

    CAS  PubMed  Google Scholar 

  37. Zuccala G, Onder G, Marzetti E, Monaco MR, Cesari M, Cocchi A, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J. 2005;26(3):226–33. doi:10.1093/eurheartj/ehi058.

    Article  CAS  PubMed  Google Scholar 

  38. Laudisio A, Marzetti E, Pagano F, Cocchi A, Bernabei R, Zuccala G. Digoxin and cognitive performance in patients with heart failure: a cohort, pharmacoepidemiological survey. Drugs Aging. 2009;26(2):103–12. doi:10.2165/0002512-200926020-00002.

    Article  CAS  PubMed  Google Scholar 

  39. Ahluwalia SC, Gross CP, Chaudhry SI, Ning YM, Leo-Summers L, Van Ness PH, et al. Impact of comorbidity on mortality among older persons with advanced heart failure. J Gen Intern Med. 2012;27(5):513–9. doi:10.1007/s11606-011-1930-3.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55(4):309–16. doi:10.1016/j.jacc.2009.07.066.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Desai RJ, Ashton CM, Deswal A, Morgan RO, Mehta HB, Chen H, et al. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012;21(3):233–40. doi:10.1002/pds.2175.

    Article  CAS  PubMed  Google Scholar 

  42. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–70.

    Article  CAS  PubMed  Google Scholar 

  43. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–60.

    Article  CAS  PubMed  Google Scholar 

  44. Little RJA, Rubin DB. The analysis of social science data with missing values. Sociol Methods Res. 1989;18(2–3):292–326. doi:10.1177/0049124189018002004.

    Article  Google Scholar 

  45. Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chen H, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012;8(5):437–44. doi:10.1016/j.jalz.2011.05.2414.

    Article  CAS  PubMed  Google Scholar 

  46. Parikh NM, Morgan RO, Kunik ME, Chen H, Aparasu RR, Yadav RK, et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011;26(7):749–57. doi:10.1002/gps.2604.

    Article  PubMed  Google Scholar 

  47. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study. BMC Gastroenterol. 2012;12:36. doi:10.1186/1471-230x-12-36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Deswal A, Petersen NJ, Souchek J, Ashton CM, Wray NP. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol. 2004;43(5):778–84. doi:10.1016/j.jacc.2003.10.033.

    Article  PubMed  Google Scholar 

  49. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Soc Adm Pharm. 2012;8(2):145–56. doi:10.1016/j.sapharm.2011.03.001.

    Article  Google Scholar 

  50. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res. 2012;1(2):195–206. doi:10.2217/cer.12.5.

    Article  PubMed  Google Scholar 

  51. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10. doi:10.1185/03007990903126833.

    Article  PubMed  Google Scholar 

  52. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615–25.

    Article  PubMed  Google Scholar 

  53. Linden A, Adams JL. Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal data. J Eval Clin Pract. 2010;16(1):180–5. doi:10.1111/j.1365-2753.2009.01361.x.

    Article  PubMed  Google Scholar 

  54. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55. doi:10.1093/biomet/70.1.41.

    Article  Google Scholar 

  55. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757–63.

    Article  CAS  PubMed  Google Scholar 

  56. Johnson ML, Bush RL, Collins TC, Lin PH, Liles DR, Henderson WG, et al. Propensity score analysis in observational studies: outcomes after abdominal aortic aneurysm repair. Am J Surg. 2006;192(3):336–43. doi:10.1016/j.amjsurg.2006.03.009.

    Article  PubMed  Google Scholar 

  57. Hernan MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med. 2002;21(12):1689–709. doi:10.1002/sim.1144.

    Article  PubMed  Google Scholar 

  58. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study. Am J Epidemiol. 2002;155(11):1045–53.

    Article  PubMed  Google Scholar 

  59. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.

    Article  PubMed  Google Scholar 

  60. Hernandez AF, Harrington RA. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ. 2008;178(10):1316–9. doi:10.1503/cmaj.080370.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. 2002;39(10):1567–73.

    Article  CAS  PubMed  Google Scholar 

  62. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins—why do we need a clinical trial? Z Kardiol. 2005;94(4):223–30. doi:10.1007/s00392-005-0210-9.

    Article  CAS  PubMed  Google Scholar 

  63. Cleland JG, Loh H, Windram J, Goode K, Clark AL. Threats, opportunities, and statins in the modern management of heart failure. Eur Heart J. 2006;27(6):641–3. doi:10.1093/eurheartj/ehi812.

    Article  PubMed  Google Scholar 

  64. Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119(1):48–53. doi:10.1016/j.ijcard.2006.07.106.

    Article  PubMed  Google Scholar 

  65. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296(17):2105–11. doi:10.1001/jama.296.17.2105.

  66. van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med. 2006;3(8):e333. doi:10.1371/journal.pmed.0030333.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (London, England: 1979). 2007;113(3):119–27. doi:10.1042/cs20070031.

  68. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–61. doi:10.1056/NEJMoa0706201.

    Article  CAS  PubMed  Google Scholar 

  69. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–9. doi:10.1016/s0140-6736(08)61240-4.

    Article  PubMed  Google Scholar 

  70. Pfister R, Schneider CA. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Eur Heart J. 2009;30(3):382–3. doi:10.1093/eurheartj/ehn560 (author reply 383).

  71. Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo Evaluation Of Memory study. J Stroke Cerebrovasc Dis. 2012;21(6):436–44. doi:10.1016/j.jstrokecerebrovasdis.2010.11.002.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80(1):13–17. doi:10.1136/jnnp.2008.150433

  73. Yadav RK, Morgan, R, Kunik, M, Chen H, Aparasu R, Johnson ML. Effect of statins on the development of dementia in elderly patients with diabetes, Houston. [Unpublished Masters thesis]. 2009 (In press).

  74. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–63. doi:10.1212/WNL.0b013e318228bf11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115(5):576–83. doi:10.1161/circulationaha.106.625574.

    Article  CAS  PubMed  Google Scholar 

  76. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43(3):317–27. doi:10.1016/j.jacc.2003.07.046.

    Article  PubMed  Google Scholar 

  77. Trewet CB, Shireman TI, Rigler SK, Howard PA. Do ACE inhibitors/angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging. 2007;24(11):945–55.

    Article  CAS  PubMed  Google Scholar 

  78. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50(5):619–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Retrospective Observational Studies, Evidera, Lexington, MA, USA

    Abhishek S. Chitnis

  2. Department of Pharmaceutical Health Outcomes and Policy, Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, 1441 Moursund Street, Houston, TX, 77030, USA

    Rajender R. Aparasu, Hua Chen & Michael L. Johnson

  3. Houston VA Health Services Research and Development, Center for Innovations in Quality, Effectiveness and Safety, and Development Center of Excellence, Houston, TX, USA

    Mark E. Kunik

  4. The University of Texas Health Science Center at Houston, Department of Neurology, Neurocognitive Disorders Center, Houston, TX, USA

    Paul E. Schulz

Authors
  1. Abhishek S. Chitnis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajender R. Aparasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark E. Kunik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul E. Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael L. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael L. Johnson.

Ethics declarations

Funding

This research was partially supported by the Houston VA HSR&D Center of Excellence (Houston Center for Quality of Care & Utilization Studies [HFP90-020]).

Conflicts of interest

Drs Chitnis, Aparasu, Chen, Kunik, Schulz and Johnson have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 131 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chitnis, A.S., Aparasu, R.R., Chen, H. et al. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs Aging 32, 743–754 (2015). https://doi.org/10.1007/s40266-015-0295-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0295-4

Keywords

Search

Navigation